Mifepristone Improves Weight Loss in Cushing’s Syndrome
Patients with Cushing’s syndrome who were administered oral mifepristone (Korlym) daily experienced significant, sustained weight loss over the years as they continued on the medication.
Patients with Cushing’s syndrome who were administered oral mifepristone (Korlym) daily experienced significant, sustained weight loss over the years as they continued on the medication.
Over 3 years of follow-up, patients experienced a reduction in frequency of episodes.
There is evidence of synergistic effect between hemoglobin HbA1c values and sodium intake.
Adults focus on quality of doctor-patient relationship rather than care provided to define quality care.
No increased risk of acute complications, cardiovascular events or death for immigrants with language barriers.
Type of birth control method may influence maternal risk for gestational diabetes.
There has been a decrease in the number of uninsured following the open enrollment period of the Affordable Care Act.
Primary care patients were more satisfied with care in shared appointments than usual care.
The percentage of teens using human growth hormone has more than doubled since 2012.
New devices include heartbeat monitor, fitness monitor and diabetes monitors.
Please login or register first to view this content.